Paul Chaplin, Bavarian Nordic CEO

With record-break­ing mpox vac­cine sales, Bavar­i­an Nordic buys trio of shots from Emer­gent for $270M cash

Bavar­i­an Nordic is putting some of its mpox vac­cine wind­falls to use, wa­ger­ing $270 mil­lion in cash to ac­quire three trav­el vac­cines — two of which …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.